PDE3, PDE4 and PKC regulate local Ca2+ releases and cardiac pacemaker firing

PDE3、PDE4 和 PKC 调节局部 Ca2 释放和心脏起搏器放电

基本信息

  • 批准号:
    8736511
  • 负责人:
  • 金额:
    $ 20.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

To test the hypothesis that combined activity of (PDE3+PDE4) impacts on basal spontaneous SANC firing via regulation of cAMP/PKA signaling, we used phosphorylation of phospholamban (PLB) at Ser16 site as a marker of cAMP/PKA-dependent protein phosphorylation in SANC. Specific PDE3 inhibitor, cilostamide (Cil, 0.3 mkmol/L), or a PDE4 inhibitor, rolipram (Rol, 2 mkmol/L), increased PLB phosphorylation by 20%, but the combination of Cil+Rol increased PLB phosphorylation by 110%, an effect similar to that (140%) produced by broad spectrum PDE inhibitor IBMX. L-type Ca2+ current (ICa,L) ensures LCR existence, providing Ca2+ available for pumping in SR. Cil or Rol alone increased the amplitude of ICa,L by 60% and 4%, respectively, while (Cil+Rol) or IBMX increased ICa,L by 100%. Cilostamide increased the spontaneous SANC firing rate (perforated patch-clamp) by 20% (from 14813 to 17513 beat/min, n=8), while rolipram produced no acceleration of spontaneous firing at 2, 20 or 100 mkmol/L. Similar to IBMX, (Cil+Rol) increased the spontaneous SANC beating rate by 50% (from 1348 to 19711 beat/min, n=9), the effect was due to a marked increase in the LCR number, size and decrease in the LCR period that predicted the concomitant decrease in the spontaneous cycle length. When RyR were disabled by ryanodine and LCRs were abolished, both IBMX and (Cil+Rol) failed to accelerate DD rate or increase SANC firing rate indicating key role of Ca2+ cycling for PDE-dependent control of spontaneous beating. We conclude that both PDE3 and PDE4 regulate spontaneous SANC firing, and a crucial role of PDE4 is revealed only when PDE3 and PDE4 are concurrently inhibited. Thus, synergism of (PDE3+PDE4) suppresses basal cAMP/PKA-dependent PLB phosphorylation and reduces ICa,L amplitude to decrease RyR Ca2+ release, prolong the LCR period and limit the spontaneous SANC firing rate.
为了验证(PDE3+PDE4)联合活性通过调节cAMP/PKA信号影响基础自发SANC放电的假设,我们使用了磷酸蛋白(PLB)在Ser16位点的磷酸化作为SANC中cAMP/PKA依赖性蛋白磷酸化的标记。特异性PDE3抑制剂西洛胺(cilostamide, 0.3 mkmol/L)或PDE4抑制剂罗利普兰(rolipram, 2 mkmol/L)可使PLB磷酸化增加20%,但Cil+Rol联合使用可使PLB磷酸化增加110%,其效果与广谱PDE抑制剂IBMX相似(140%)。L型Ca2+电流(ICa,L)保证了LCR的存在,为sr提供了可泵送的Ca2+。Cil或Rol单独使ICa,L的幅度分别增加了60%和4%,而(Cil+Rol)或IBMX使ICa,L增加了100%。西洛他胺使SANC自发放电速率(穿孔膜片钳)增加20%(从14813到17513次/分钟,n=8),而罗利普兰在2、20和100 mkmol/L时没有加速自发放电。与IBMX相似,(Cil+Rol)使SANC自发心跳率提高了50%(从1348次心跳/分钟增加到19711次心跳/分钟,n=9),其效果是由于LCR数量和大小的显著增加以及LCR周期的减少,这预示着自发周期长度的减少。当RyR被ryanodine禁用和lcr被废除时,IBMX和(Cil+Rol)都不能加速DD速率或增加SANC放电速率,这表明Ca2+循环在pde依赖性的自发搏动控制中起关键作用。我们得出结论,PDE3和PDE4都能调节自发的SANC放电,只有当PDE3和PDE4同时被抑制时,PDE4的关键作用才会被揭示。因此,(PDE3+PDE4)的协同作用抑制了基础cAMP/ pka依赖的PLB磷酸化,降低了ICa,L振幅,减少了RyR Ca2+的释放,延长了LCR周期,限制了自发的SANC放电速率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward Lakatta其他文献

Edward Lakatta的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward Lakatta', 18)}}的其他基金

A PUFA Dietary Intervention for Heart Rate
PUFA 饮食干预心率
  • 批准号:
    8335786
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Decreased pacemaker activity in aged sinoatrial node
老年窦房结起搏器活动减少
  • 批准号:
    8335801
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
用于治疗应用的高级糖基化终产物的可溶性受体
  • 批准号:
    8552494
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
EPO 及其衍生物降低血压的治疗潜力
  • 批准号:
    9147229
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
The VALIDATE study
验证研究
  • 批准号:
    8736504
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
The REVEAL study
REVEAL 研究
  • 批准号:
    8552344
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Effects Of Age And Conditioning Status On Rest And Exercise Cardiac Performance
年龄和体能状态对休息和运动心脏功能的影响
  • 批准号:
    8931601
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Matching ATP supply and demand in cardiac pacemaker cells
匹配心脏起搏细胞中的 ATP 供应和需求
  • 批准号:
    8931611
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
Age-Associated Changes in Arterial Proteome and Aortic Smooth Muscle Signaling
动脉蛋白质组和主动脉平滑肌信号与年龄相关的变化
  • 批准号:
    8931487
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
A PUFA Dietary Intervention for Heart Rate
PUFA 饮食干预心率
  • 批准号:
    8552336
  • 财政年份:
  • 资助金额:
    $ 20.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了